Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
2022studies shown
Showing 1,326-1,350 of 2,022
Not Yet RecruitingNCT06971328

ACT-Based Psychoeducation for Schizophrenia Caregivers

This study exists to see whether acceptance and commitment therapy, a talking treatment, can play a useful role in care. Researchers are trying to understand what acceptance and commitment therapy, a talking treatment, could change in day-to-day care and decision-making.

SchizophreniaOtherOver 18 Months
Countries
Turkey
Sponsor
Ataturk University
Condition
Schizophrenia
TerminatedNCT03351244

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can better prevent setbacks and support longer-term stability.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
Canada, France, Japan, South Korea, Spain, Taiwan, United States
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
RecruitingNCT06386588

The Effects of Auditory Stimulation During Sleep on Brain Networks in Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 45 Years
Countries
United States
Sponsor
Massachusetts General Hospital
Condition
Schizophrenia
Not Yet RecruitingNCT06964477

A Trial of Extended Reality Activities to Enhance Leisure Participation Among Inpatients With Persistent Mental Health Conditions

This study exists to understand how the medication Extended holds up over time after the earliest research stage. Researchers are trying to understand whether the medication Extended can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 20 Years to 65 Years
Countries
Taiwan
Sponsor
Chia-Hui Hung
Condition
Schizophrenia
CompletedNCT05944510

Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand what this type of care could change in day-to-day care and decision-making.

SchizophreniaOtherOver 18 Years
Countries
India
Sponsor
All India Institute of Medical Sciences, Bhubaneswar
Condition
Schizophrenia
Not Yet RecruitingNCT06938997

The Effectiveness of Combining AR/VR Technology in Virtual Clinical Auditory Hallucinations on the Comprehensive Auditory Hallucination Nursing Competency of Psychiatric Nurses

This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can make support easier to access outside standard clinic visits.

SchizophreniaOtherFrom 20 Years to 65 Years
Countries
Taiwan
Sponsor
National Yang Ming Chiao Tung University
Condition
Schizophrenia
RecruitingNCT06958341

Neuroimmunology Registry and Biobank

This study exists to see whether a therapy or guided support program can make care clearer and more responsive. Researchers are trying to understand whether a therapy or guided support program can give earlier or clearer feedback during care.

SchizophreniaOther
Countries
Germany
Sponsor
Charite University, Berlin, Germany
Condition
Schizophrenia
RecruitingNCT06835556

Volatility in Paranoia (VIP) Trial: An RCT of Changes in Volatility With Psychotherapy

This study exists to see whether cognitive behavioural therapy, a structured talking treatment, can make care clearer and more responsive. Researchers are trying to understand whether cognitive behavioural therapy, a structured talking treatment, can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Vanderbilt University Medical Center
Condition
Schizophrenia
Active Not RecruitingNCT06245213

A Study of ANAVEX3-71 in Adults With Schizophrenia

This study exists to understand whether the medication ANAVEX3-71 is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to the medication ANAVEX3-71 in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Anavex Life Sciences Corp.
Condition
Schizophrenia
Active Not RecruitingNCT06453174

CLinical Utility of Early Intervention Including the 5-Step Precision Medicine (5SPM) Method in First-episode Psychosis: The CLUMP Project

This study exists to understand what helps a medication treatment work in everyday practice, not just under ideal conditions. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

SchizophreniaOtherFrom 12 Years to 35 Years
Countries
Spain
Sponsor
Instituto de Investigación Biomédica de Salamanca
Condition
Schizophrenia
CompletedNCT02431702

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

This study exists to compare options and see whether brain scans or other body measurements offers something meaningfully different. Researchers are trying to understand whether brain scans or other body measurements can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 35 Years
Countries
Brazil, Mexico, United States
Sponsor
Janssen Scientific Affairs, LLC
Condition
Schizophrenia
CompletedNCT03345342

A Study of Paliperidone Palmitate 6-Month Formulation

This study exists to explore whether the medication Paliperidone could improve care and understanding. Researchers are trying to understand whether the medication Paliperidone can better prevent setbacks and support longer-term stability.

SchizophreniaOtherFrom 18 Years to 70 Years
Countries
Argentina, Australia, Brazil, Bulgaria, Czech Republic, France, China, Hungary, India, Italy, Malaysia, Mexico, Poland, Russian Federation, South Africa, South Korea, Spain, Taiwan, Turkey, Ukraine, United States
Sponsor
Janssen Research & Development, LLC
Condition
Schizophrenia
CompletedNCT01819818

A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients

This study exists to better understand the safety of a digital app or remote support tool and how manageable it feels in practice. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOther
Countries
South Korea
Sponsor
Janssen Korea, Ltd., Korea
Condition
Schizophrenia
CompletedNCT03629951

A Study for Schizophrenia Relapse Prediction

This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand whether this type of care can better prevent setbacks and support longer-term stability.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
India
Sponsor
Janssen Research & Development, LLC
Condition
Schizophrenia
CompletedNCT03713658

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

This study exists to see whether the medication Oral is workable and worth testing more broadly. Researchers are trying to understand what the medication Oral could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 70 Years
Countries
Rwanda
Sponsor
Janssen Research & Development, LLC
Condition
Schizophrenia
CompletedNCT00460512

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia

This study exists to understand whether the medication Flexibly is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to the medication Flexibly in practice and what may need to be adjusted.

SchizophreniaOtherOver 18 Years
Countries
Belgium, Bulgaria, Croatia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Latvia, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Serbia, Spain, Sweden, Switzerland, Turkey, United Kingdom
Sponsor
Janssen-Cilag International NV
Condition
Schizophrenia
CompletedNCT02713282

A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

This study exists to explore whether the medication Transition could improve care and understanding. Researchers are trying to understand whether the medication Transition can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
Croatia, Denmark, France, Germany, Greece, Israel, Malaysia, Netherlands, Russian Federation, Saudi Arabia, South Korea, Spain, Taiwan, Turkey, United Kingdom
Sponsor
Janssen-Cilag Ltd.
Condition
Schizophrenia
CompletedNCT03571685

Sustainable Early Episode Clinic Study (SEEC)

This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand whether this type of care can better prevent setbacks and support longer-term stability.

SchizophreniaOtherOver 18 Years
Countries
United States
Sponsor
Janssen Scientific Affairs, LLC
Condition
Schizophrenia
CompletedNCT03809325

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

This study exists to explore whether questionnaires and follow-up reports could improve care and understanding. Researchers are trying to understand what questionnaires and follow-up reports could change in day-to-day care and decision-making.

SchizophreniaOtherOver 18 Years
Countries
Belgium, France, Germany, Hungary, Italy, Spain, United Kingdom
Sponsor
Janssen-Cilag International NV
Condition
Schizophrenia
Schizophrenia | Clinical Trials | HopeStage Research